salem femasys investors llc  pooled investment fund dyett formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local salem femasys investors llc industry pooled investment fund see others in industry address  santa monica blvd suite  los angeles ca phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  new   equity only b sec link  new   equity only b sec link  new   equity only b sec link directors and executives current and past name role john dyett promoter   salem femasys investors llc  list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors salem femasys investors llc list of persons related to the company salem femasys investors llc find out list of ceos founders board members and company directors of salem femasys investors llc cik number 0company address  santa monica blvd suite  los angeles phone number  people related to salem femasys investors llc namepositionstreetcitycountrydyett john santa monica blvd suite los angelesca salem femasys investors llc on the web related companiessalem x fund lp salem global opportunity fund offshore ltd salem global opportunity fund lp salem hotel group llc salem investment partners iii limited partnership salem investment partners iv limited partnership salem lakes storage llc salem ridge apartments llc salem sebacia investors llc salem surgery center ltd salem zs investors llc salemarked inc salemove inc femasys completes  million series b financing round femasys completes  million series b financing round apr    et from femasys inc femasys inc     facebook twitter pinterest femasys inc atlanta april   prnewswire  femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round  the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics  salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants  the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system    we are pleased to have the support and confidence of this esteemed group of investors said kathy leesepsick femasys president and ceo this round of funding will enable femasys to invest in the people and programs necessary to achieve the investigational device exemption ide milestone for fembloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about femasys inc  wwwfemasyscom  femasys inc based in atlanta ga is a privately held corporation committed to advancing womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact  additional information about femasys and the companys products can be found at wwwfemasyscom about legacy capital partners john adams jr was the former ceo of adams respiratory therapeutics developer of the mucinex brands adams was sold to reckitt benckiser in 0 for  billion  mr adams has been in the pharmaceutical industry for over 0 years and has made investments in a number of developmentstage companies  legacy capital partners is based in southlake tx about mario family partners mario family partners is the private equity arm of dr ernest marios family office  dr mario was the former ceo of alza corporation which was sold to johnson  johnson for  billion in 0 the largestever ma deal for jj at the time  he was previously ceo of glaxo and currently sits on the boards of boston scientific corporation and celgene corporation among others about salem partners llc  wwwsalempartnerscom salem partners is a boutique investment bank and wealth management firm based in los angeles that specializes in raising growth capital and executing ma assignments for companies in the media life sciences and industrial sectors  salem has a strong track record in life sciences having raised substantially all of the private capital for adams respiratory therapeutics zs pharma inc and neos therapeutics femasys fembloc femvue and femcerv are registered trademarks of femasys inc  all rights reserved media contact             jerry fink  logo  httpphotosprnewswirecomprnh0cllogo  source femasys inc related links httpwwwfemasyscom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul    et preview femasys secures term loan facility from silicon valley bank jul    et preview femasys signs distribution agreement with mckesson medicalsurgical for femcerv device for diagnosis of cervical cancer my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within 0 days ext0 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext0 legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within 0 days ext0 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext0 legal privacy  cookies   microsoft femasys inc raises m – massdevice massdevicethe medical device business journal — medical device news  articles  massdevice home » femasys inc raises mfemasys inc raises m january   by sarah faulkner leave a comment femasys inc said last week that it raised  million according to a regulatory document filed with the sec atlantabased femasys wrote that  investors contributed to the round and that it paid los angelesbased investment bank salem partners llc an estimated 00 in sales commissions the st sale in the financing round happened on jan  this year the company said in its filing in december last year femasys closed a 0 million series c round that it said it will use to fund a pivotal trial for its fembloc permanent female contraception device the financing round was arranged and led by salem partners with “multiple institutional investors family offices and a multibilliondollar global medical device company” also contributing the company touts its fembloc as a nonsurgical procedure that can be done at the doctor’s office and is designed to obstruct the fallopain tubes femasys won an investigational device exemption from the fda in december to conduct the st clinical trial for the proposed indication of the fembloc system “fembloc is designed to fill the unmet need of a safe permanent contraceptive method that can be easily implemented since it does not require specialized surgical skills or investment in costly surgical equipment” clinical affairs vp dr mimi zieman said “this contrasts with current female sterilization options that have the inconvenience and risks associated with surgery and anesthesia for tubal ligation and for hysteroscopic procedures – the challenge of placing the devices correctly and concerns with longterm use” in case you missed it omnicell shares surge after q beat slug slime inspires new surgical glue haemonetics wins fda k for nexsys pcs plasmapheresis system cyber attack stalls manufacturing for merck narrows outlook  medtech stories we missed this week july   integer misses expectations on q profits but grows revenue nuvasive shares drop amid mixed q earnings reorganization efforts quantitative insights wins fda de novo nod for quantx machine learning cancer diag trumpcare goes down on no vote for ‘skinny repeal’ atricure gains on q revenue beat raised outlook titan medical closes m offering tandem shares slide after q sales miss prolonging the lives  independence of alzheimer’s patients with artificial intelligence hillrom slips on fiscal q sales miss lowered outlook stryker’s q earnings beat prompts raised outlook boston scientific warns on fluke sicd death fda sets inaugural meeting of firstever patient engagement advisory committee from medical design  outsourcing fda sets inaugural meeting of firstever patient engagement advisory committeeby kathryn o’callaghan and jeffrey shuren md jd imagine checking your blood sugar levels several times a day with a glucose meter to keep your diabetes under control or maybe you’ve had a hip joint replaced or a stent inserted in your coronary artery to treat a heart blockage maybe you participated in a clinical …these wheelchair wheels function like airplane landing gearfrog legs has partnered with plasticomp to make carbon fiber composite wheelchair caster wheels that function like airplane landing gear for a smoother ride frog legs wanted to switch the wheels of its wheelchairs from machined aluminum to carbon fiber composite mark chelgren the company’s founder also wanted to create a wheelchair that had a …patients don’t have to lose weight for joint replacement surgeriesobese patients who are having knee or hip replacement surgery don’t need to lose weight prior to surgery to reap the benefits according to a new study from the university of massachusetts medical school “our data shows it’s not necessary to ask patients to lose weight prior to surgery” said wenjun li lead author on … ways neurostimulation could make our lives betterneurostimulation is being used for a lot of different things that go beyond motor disorders and diseases neurostimulation is used to stimulate certain parts of the brain’s nervous system it can be invasive with implants or it can be noninvasive with electrodefilled caps and ear clips the neurostimulation market was worth an estimated  billion …wisconsin biotech industry optimistic about state’s foxconn winwisconsin’s biotech industry sees opportunity in taiwanese electronics giant foxconn’s decision to spend  billion on a employee plant in the state’s southeast that’s because the k liquid crystal display lcd screens made at the new foxconn campus could enable new medical solutions for surgical procedures according to bioforward wisconsin “bioforward and wisconsin’s biohealth community welcomes …icon beats street on q earnings acquires mapi groupdrug development provider icon plc nasdaq iclr saw its stock jump about  in value today after announcing secondquarter earnings that beat analysts’ expectations the dublin ireland–based company which serves the pharmaceutical biotechnology and medical device industries also said it has acquired the mapi group which provides patientcentered health outcomes research and commercialisation financial terms of …could this athome monitoring device make the elderly more independenta university of illinois at urbanachampaign student developed a home monitoring device that allows the elderly to live alone without families worrying about them according to a case study from model solution milpitas calif jun young park a senior industrial design student led by professor sung too shin created the incair athome monitoring device to help … innovative medical devices designed by studentsthe industrial designers society of america idsa just released its list of the  idea awardwinning designed products the winners in the medical device category included several interesting devices but what really caught our eye was the student designs category which featured several noteworthy medical innovations these devices were interesting because of their focus on …gi dynamics taps proven process as endobarrier manufacturergi dynamics asxgid said today it inked a contract manufacturing partnership deal with proven process medical devices through the deal proven process will manufacture bostonbased gi dynamic’s endobarrier device at its mansfield massbased facilities the endobarrier is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the …how a builtin refrigerator ice dispenser can dispense medicationan arizona state university student recently designed an automatic medicine dispenser that could replace water and ice dispensers on refrigerators according to a case study from model solution milpitas calif the device can dispense pills for two different users and gives audio and visual signals for the times that the users have to take their …chinese regulators identify first round of medical device clinical trial inspectionsby stewart eisenhart emergo group following its recent announcement of a new inspection program for medical device clinical trial sites the china food and drug administration cfda has identified the first round of sites that will undergo such inspections get the full story here at the emergo group’s blog the opinions expressed in this blog … leave a reply cancel replyyou must be logged in to post a comment need medtech news in a minute we deliver massdevice enewsletters get you caught up on all the mission critical news you need in med tech sign up today tweets by massdevice massdevice medical network devicetalks drug delivery business news medical design  outsourcing massdevice subscribe to massdevice advertise with us about contact us privacy massdevice network massdevice linkedin google femasys inc making a differencein the lives of women one product at a time is a great privilege that drives the companys mission read more fembloc™ permanent contraceptive systemrevolutionizing family planning options for women read more the fembloc™ solution femasys is developing a permanent contraceptive solution fembloc™ that will provide a safe and effective family planning option for women who want to be free from temporary methods fembloc has been designed for widespread acceptance by physicians and their patients every gynecologist can perform inoffice simple nonsurgical placement using known intrauterine techniques safe and natural approach for patients pregnancy prevention by the body’s natural response to a temporary biopolymer with no intrusive implants or hormones least expensive convenient permanent option this office based procedure eliminates all extra costs to the practice and patient such as anesthesia hospitalequipment fees and radiology referrals fembloc™ permanent contraceptive system is not commercially available for sale 0 of all women using contraceptives no longer want more children   daniels k et al current contraceptive status among women aged  united states  national center for health statistics dec   jones j et al current contraceptive use in the united states 00 and changes in patterns of use since  national health statistics reports no 0 oct  products currently making a difference femasys has expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler about femvue the femvue® salineair device is used to introduce a consistent mixture of saline and air contrast in a controlled fashion for the tubal evaluation portion of the sono hsg the bright echoes of the air bubbles can be seen flowing into and through each fallopian tube providing physicians an effective contrast to make a tubal patency determination learn more about sono hsg sono hsg also called sonographic hysterosalpingogram is a transvaginal ultrasound technique that involves assessment of fallopian tube patency with a mixture of air and saline delivered through an intrauterine catheter as well as detection of abnormalities of the uterus learn more  gynecology in practice infertility edited by emre seli chapter  diagnosis and management of tubal factor infertility amanda n kallen and peter h kodamanspan   learn more about femcerv at wwwfemcervcom about us femasys inc is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact our products have been organically conceived researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the us food and drug administration fda per the requirements of  cfr 0 as well as iso  femasys has achieved significant milestones to date including numerous issued patents and filings clearance of multiple regulatory filings by the us fda european union canada and japan with other select countries in process our process  invent  develop  test  approve  build  market leadership kathy leesepsickpresident  ceo founder of femasys inc has served as president  ceo overseeing the development of the company since its inception she has over 0 years experience in medical device management directing product development operations and commercialization efforts in medical product regulated markets globally and is the inventor on more than 0 patents and patent applications jeffrey marcus md chief medical advisor practicing obstetrician gynecologist has influenced the company’s product development including intellectual property and commercialization efforts he has over 0 years of experience as a physician and was a founding member of atlanta womens health group he has served as a principal investigator of numerous clinical trials and as a member of medical advisory and speaker boards todd creechchief financial advisor has been involved since  and is responsible for overseeing the company’s financing accounting corporate development and investor activities he has over 0 years of experience where he has structured placed and managed capital investments raising millions in debt and equity financing for emerging companies such as zs pharma sarcode bioscience sirion therapeutics novaquest and centice also serves as a partner at healthquest capital daniel curriesenior vp operations has served as head of operations developing the companys infrastructure product development program and quality system foundation since its inception he has over  years of operational experience in the medical device industry working closely with research and development teams implementing and managing quality systems and developing fully compliant manufacturing operations both domestically and internationally lisa peacockvp regulatory affairs has served as vp overseeing global regulatory product approvals since 0 she has over 0 years of experience in medical device development compliance and global regulatory product approvals and has led product strategy and development initiatives for class iii medical devices that have successfully achieved pma approval and managed preclinical and quality aspects for groundbreaking technologies mimi zieman md vp clinical affairs has served as vp overseeing global clinical trial activities since  she has over 0 years of consulting experience in womens health and contraception medical education pharmacovigilance and clinical trial development she was the director of family planning for  years at grady memorial hospital and emory university where she founded a family planning fellowship program steven damon vp business  commercial development has served as vp since  overseeing strategic partnerships including distribution arrangements mr damon has over  years of experience in pharmaceutical and medical device business management in the us and europe with a track record of securing several key partnerships with pharmaceutical companies resulting in more than  million of nondilutive financing gary thompsonvp finance  administration has served as vp since 0 and has over 0 years of finance and management experience in the medical device and pharmaceutical industries and public accounting as a cpa for both growth and revenue generating stage companies he uniquely served as head of finance for a emerging unit within cr bard and was responsible for budgeting strategic plans and reporting tim pruittvp manufacturing has been involved since  and is responsible for overseeing the company’s manufacturing he has over 0 years of experience including machine design product development process engineering and operations for the manufacturing and distribution of medical devices and tissue products for companies such as cryolife cr bard aderans and novoste news dec  mar  dec  jul  apr  femasys appoints fred aslan and charles larsen to its board of directors atlanta ga march   femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office read more femasys announces todd creech as chief financial officer atlanta ga december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities read more femasys secures term loan facility from silicon valley bank atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device read more femasys completes  million series b financing round atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor read more femasys announces 0 million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early   atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed 0 million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office read more corporate contacts general information infofemasyscom employment hrfemasyscom business development steve damon  sdamonfemasyscom media  public relations jerry fink  jfinkfemasyscom femvue orders  customer service united states orders  femasys monfri 0 am  0 pm et toll free  customerservicefemasyscom fax 0 wwwfemvuecom japan orders  bayer healthcare bayer diagnostics japan femcerv orders  customer service united states  mckesson medicalsurgical toll free  wwwfemcervcom corporate headquarters femasys inc 0 johns creek court suite 0 suwanee ga 00 p  f 0 send message femasys announces todd creech as chief financial officer x atlanta ga  december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities todd has a tremendous amount of financial and corporate development experience in the life sciences industry we are honored to welcome todd to the femasys team as we enter the next critical phase of growth while pursuing our vision of expanding healthcare options for women with our innovative medical devices said kathy leesepsick femasys president and ceo todds proven track record and financial leadership is exemplified by his success with numerous debt and equity financings to support the development of latestage programs regulatory approvals as well as commercial activities mr creech previously served as the chief financial officer of zs pharma inc from august  until june  and was part of the team responsible for taking the company public completing a successful secondary offering disseminating key clinical data and positioning the company for ma discussions and eventual acquisition during his tenure at zs pharma mr creech helped raise approximately 0 million in debt and equity financing prior to zs pharma mr creech was cfo and vice president of business development at sarcode bioscience where he led all financing legal accounting and corporate development activities shire pharmaceuticals acquired sarcode in april  prior to sarcode mr creech was cfo of sirion therapeutics an ophthalmic pharmaceutical company during his tenure he raised 0 million in debt and equity financing to support the development of six latestage clinical programs and two nda approvals and he also helped lead the sale of sirions drug assets to alcon and bausch  lomb mr creech worked with novaquest the investment group within quintiles inc where he structured placed and managed capital investments into usemerging biotech and specialty pharmaceutical companies prior to his work with novaquest he cofounded centice an optical sensor spin out from duke university in 00 mr creech has an additional  years of experience consulting to biotech and hightech companies while at sri international and andersen consulting mr creech holds bachelors degrees in finance and accounting from miami university of ohio and an mba from duke university this is an extremely exciting time to be joining femasys especially as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered in exclusively in the office said mr creech i look forward to working closely with the femasys team to achieve its financial and strategic goals femasys secures term loan facility from silicon valley bank × atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device we are pleased to build a relationship with silicon valley bank a leader in financial services for the healthcare industry this loan facility will provide greater financial flexibility as we aggressively pursue the regulatory milestones of our highly promising fembloc™ permanent contraceptive system and expansion of commercialization efforts for our novel medical devices remarked kathy leesepsick president  ceo of femasys inc the opportunity to work with innovative medical device companies like femasys is what excites us on the life science side of the svb portfolio said scott mccarty director of life science and healthcare for silicon valley banks atlanta office we have confidence in the femasys team and it has been a pleasure working with them throughout the implementation of the loan facility our partnership is intended to increase the companys probability of success as it develops and delivers solutions that are transforming womens healthcare femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about silicon valley bank  wwwsvbcom for more than 0 years silicon valley bank svb has helped innovative companies and their investors move bold ideas forward fast svb provides targeted financial services and expertise through its offices in innovation centers around the world with commercial international and private banking services svb helps address the unique needs of innovators forbes named svb one of americas best banks  and one of americas bestmanaged companies  learn more at svbcom silicon valley bank is the california bank subsidiary and commercial banking operation of svb financial group nasdaq sivb and a member of the fdic silicon valley bank and svb financial group are members of the federal reserve system femasys completes  million series b financing round × atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system we are pleased to have the support and confidence of this esteemed group of investors said kathy leesepsick femasys president and ceo this round of funding will enable femasys to invest in the people and programs necessary to achieve the investigational device exemption ide milestone for fembloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about legacy capital partners john adams jr was the former ceo of adams respiratory therapeutics developer of the mucinex brands adams was sold to reckitt benckiser in 0 for  billion mr adams has been in the pharmaceutical industry for over 0 years and has made investments in a number of developmentstage companies legacy capital partners is based in southlake tx about mario family partners mario family partners is the private equity arm of dr ernest marios family office dr mario was the former ceo of alza corporation which was sold to johnson  johnson for  billion in 0 the largestever ma deal for jj at the time he was previously ceo of glaxo and currently sits on the boards of boston scientific corporation and celgene corporation among others about salem partners llc  wwwsalempartnerscom salem partners is a boutique investment bank and wealth management firm based in los angeles that specializes in raising growth capital and executing ma assignments for companies in the media life sciences and industrial sectors salem has a strong track record in life sciences having raised substantially all of the private capital for adams respiratory therapeutics zs pharma inc and neos therapeutics femasys appoints fred aslan and charles larsen to its board of directors ×  aslan and larsen are seasoned healthcare executives who have successfully developed emerging technologies to advance the practice of medicine  atlanta ga march    femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office we are extremely honored to have fred and charlie join our board of directors – they are proven executives who have been successful starting new businesses developing and commercializing emerging technologies building organizations and delivering value to shareholders” said kathy leesepsick president and ceo of femasys “their considerable experience will be invaluable to our team as we embark on the next phase of development with fembloc™” dr aslan has over  years of strategic management and direct investment experience in the medical device diagnostics and biotechnology sectors dr aslan is currently the founder and chief executive officer of advance medical a venrock portfolio company that is focused on the commercialization of medical device and diagnostics technologies in brazil and he is also a vice president at venrock dr aslan has served on the board of directors of receptos a company recently acquired by celgene and has been a board observer for a number of other companies including zeltiq and powervision dr aslan was the director of business development and investor relations at curagen corporation prior to curagen he worked at boston consulting group where he advised biotechnology and pharmaceutical companies on a number of strategic initiatives dr aslan received his bs in biology from duke university md from yale university school of medicine and mba from the harvard business school mr larsen has over  years of operating and technical experience in the medical device industry he cofounded novoste corporation and the innovation factory and through his role at the innovation factory he cofounded additional companies including acufocus aquesys halscion liposonix neuronetics and sebacia he holds over 0 issued us and international patents on medical devices before joining novoste mr larsen held positions with novoste puerto rico cordis corporation key pharmaceuticals and parkedaviswarner lambert in executive senior engineering and project management roles mr larsen received a bs in mechanical engineering from the new jersey institute of technology mr larsen currently is member of the board of directors for acufocus cardiofocus intuity and torax about femasys femasys inc based in atlanta ga is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the company’s products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system femasys announces 0 million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early   × atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed 0 million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office we are thrilled with the level of enthusiasm in this oversubscribed round of funding and grateful for the backing from our new and existing investors said kathy leesepsick femasys president and ceo their financial investment enables us to conduct and complete the fembloc clinical plan which will support our planned premarket approval application pma and ultimately our vision of improving the lives of women by providing access to an ideal permanent contraception solution that is safe and highly effective for women in the us and worldwide femasys also announced that it has gained us food and drug administration fda investigational device exemption ide approval to launch a prospective multicenter clinical trial to evaluate the safety of the fembloc permanent contraceptive system while preventing pregnancy the clinical trial which will enroll women who desire permanent birth control by occlusion of the fallopian tubes will be the companys first trial to evaluate the complete fembloc contraceptive system for its intended use fembloc is designed to fill the unmet need of a safe permanent contraceptive method that can be easily implemented since it does not require specialized surgical skills or investment in costly surgical equipment said mimi zieman md vice president of clinical affairs at femasys and a board certified obgyn specializing in family planning this contrasts with current female sterilization options that have the inconvenience and risks associated with surgery and anesthesia for tubal ligation and for hysteroscopic procedures  the challenge of placing the devices correctly and concerns with longterm use dechert llp served as legal counsel to femasys inc while baker botts llp served as investor counsel about femasys femasys is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the companys products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization solution fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system fembloc permanent contraceptive system is not commercially available for sale femasys fembloc femvue and femcerv are registered trademarks of femasys inc all rights reserved terms  privacy × this site and any related services are provided subject to these terms and conditions please read the following information carefully your continued use of this website will indicate your agreement to be bound by the terms and conditions set forth belowif you do not wish to be bound by these terms and conditions please do not use or access this website femasys may modify the terms and conditions at any time and such modifications will be effective immediately upon posting to the website please review the terms of use and privacy policy each time you visit the femasys website purpose this is a world wide web site for information about femasys inc products fembloc femcerv and femvue and sono hsg the purpose is to provide information to healthcare providers patients and all interested parties copyright all rights including copyright in the content of the web pages contained in this website are owned or controlled for these purposes by femasys inc in accessing femasys web pages you agree that you may only download the content for your personal noncommercial use you are not permitted to copy reproduce republish distribute broadcast download store in any medium transmit show or play in public adapt or change in any way the content of these femasys web pages for any other purpose whatsoever without the prior written permission of femasys inc security unauthorized attempts to upload information or change information on this web site are strictly prohibited and may be punishable under the computer fraud and abuse act of  and the national information infrastructure protection act for site security purposes and to ensure that this service remains available to all users this server employs software programs to monitor network traffic to identify unauthorized attempts to upload or change information or otherwise cause damage trademark notice femasys is a trademark of femasys inc other trademarks logos brand names and slogans registered or used by femasys in the united states andor other countries include but are not limited to the following fembloc femcerv femchec femaseed and femvue all other trademarks and registered trademarks are the property of their respective owners privacy policyexcept to maintain required correspondence files no other attempts are made to identify individual users or their usage habits raw data logs are used to determine how many users are accessing the site which pages are most popular and from time to time from which top level domain users are coming no personally identifying information about you will be obtained when you visit this site unless you choose to provide such information to us if you choose to send an email to points of contact on the site any information you provide will be used solely to respond to your request salem femasys investors llc  funding history company info news  want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus0 deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basecompaniessalemfemasysinvestorsllcsectioncompaniessubsectiondetailid   search deals by company name industry location investors search salem femasys investors llccompany detailsget alertedif salem femasys investors llc gets fundedsalem femasys investors llcfunding history key peoplecountrystatecityunited statescalifornialos angelesindustryfinance funding history datedeal sizeinvestors april st view dealcreate alertmanage your alerts in accountwant to know when salem femasys investors llc gets fundedkey peoplejohn dyettpromoterplease note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completeinaccurate data help us improve whogotfunded post a comment